Regulatory requirements deficiencies

End-user software acceptability testing is frequently performed to satisfy regulatory requirements however, it is also used to ensure system validity and identify deficiencies. 

Historically, the regulatory requirements for the assessment of the carcinogenic potential of pharmaceuticals recommended the conduct of long-term carcinogenicity studies in two rodent species, usually the rat and the mouse. In the 1990s, the use of transgenic mice was introduced in an attempt to improve the process of hazard identification.24 Deficiencies of the conventional bioassay are well known and include the following 25-26... 

QA s task to identify noncompliance with regulatory requirements, the trial protocol and internal procedures such as SOPs is not always an easy job. Communicating deficiencies and highlighting inadequate procedures is certainly a benefit for the company as a whole, but the individual may not appreciate being confronted with audit findings (Winchell, 2004). In order to be efficient and effective in QA, the following should be observed. 

Section 396.13(b) and (c) also closes the loop on the DVIR process. It states your drivers must review the last DVIR and sign the report only if safety-related defects or deficiencies were noted and repairs to same were made. This is the only reporting requirement pertaining to the pre-trip. Unlike the post-trip inspection, which requires the completion of the DVIR, there are no required forms or reports for the pre-trip. Some carriers use a company pre-trip form to document the pre-trip as a matter of company policy, but there is no regulatory requirement. 

Regulatory History. Past history in terms of an organization s ability to comply with regulatory requirements is one indicator of the need for additional staffing. If past practices have been deficient and if an organization has come under enforcement action as a result of such deficiencies, an evaluation should be conducted to determine the number of staff and area of expertise that would be required to bring the organization into compliance. 

The closing down of the clinical trial at the site after the last visit of the last study subject has finished and all the CRFs are completed is an important part of the clinical trial. The process of archiving the documentation, both at the site and at the sponsor office, needs to take place -ideally as soon as possible after the end of the clinical phase of the study. The effort required to do this well is very much less than that which will be required if deficiencies are identified later -particularly if that occurs during a regulatory authority inspection ... 

Where FDA determines any deviation from GMP, the inspector leaves a form, FDA-483, specifying the manufacturing deficiencies. It is essential in these circumstances that the company immediately make all corrections and respond to FDA in writing about them. It can be expected that FDA will reinspect the establishment and look both for what has been done to correct the prior deficiencies and for any new deficiencies that can be found. The pharmaceutical industry believes that FDAoften lists insignificant matters, that establishments which have passed without observed deficiencies in the past suddenly will be the subject of major deficiencies because of a change of inspectors or of interpretation, and that the requirements vary widely from individual inspector to individual inspector and from FDA district to FDA district. The industry has found, however, that its complaints fall on deaf ears, and thus that it must comply with whatever is required by the individual inspector or face the threat of serious regulatory action. 

Many companies are only prepared to meet regulatory expectations and provide the minimum requirements. The goal of assessment is not to appease the regulatory agencies but to build quality into the various systems, identify deficiencies early on, identify the genesis of system failures, and ensure continuous improvement. There are myriad resources available from which information can be captured and utilized to assist with the benchmarking initiative. 

These observations suggest that vitamin E may play a regulatory role in PG biosynthesis by controlling the formation of key intermediates such as hydroperoxides and cyclic endoperoxides. In these experiments, peroxidase activity associated with the PGH synthase could not be measured because of the contamination of other peroxidases like cyt P-450 hydroperoxidase in crude microsomal preparations. Our attempts to measure the differences in catalytic rates employing indomethacin were not successful. Nevertheless, it is not too unreasonable to assume that probably both activities of PGH synthase are equally affected by vitamin E deficiency, since both require heme as cofactor. 

---